Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond

SIMPLE SUMMARY: Relapsed or refractory (r/r) lymphomas represent hard-to-treat cancers with dismal prognoses. Over the past few years, immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have changed treatment paradigms in many mal...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrone, Salvatore, Lopedote, Paolo, De Sanctis, Vitaliana, Iamundo De Cumis, Ilenia, Pulsoni, Alessandro, Strati, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216471/
https://www.ncbi.nlm.nih.gov/pubmed/37345088
http://dx.doi.org/10.3390/cancers15102751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216471/
https://www.ncbi.nlm.nih.gov/pubmed/37345088
http://dx.doi.org/10.3390/cancers15102751

Ejemplares similares